Category
103 articles — page 4 of 9
Pseudocatalase cream (PC-KUS) is frequently asked about in vitiligo communities. The evidence is weak, the mechanism is contested, and the product is not widely available. Here is the honest assessment.
PUVA — psoralen plus UVA — was the standard phototherapy for vitiligo for decades before narrowband UVB became dominant. It still has a role in specific situations. Here is how it works and how it compares to NbUVB.
Ruxolitinib cream (Opzelura) and tacrolimus are the two most-discussed topical treatments for vitiligo. They work by different mechanisms, have different evidence bases, and suit different patients. Here is the direct head-to-head comparison.
Tofacitinib is an oral JAK inhibitor used off-label for vitiligo, with a growing body of case series and small trial evidence. It predates ruxolitinib and baricitinib as a JAK inhibitor in clinical use, but carries a more complex safety profile.
Vitiligo and alopecia areata co-occur more frequently than chance would predict, share autoimmune mechanisms, and — critically — both respond to JAK inhibitors. Understanding the overlap has real treatment implications.
Atopic dermatitis (eczema) co-occurs with vitiligo at elevated rates, and both conditions respond to topical calcineurin inhibitors. Here is how to manage the two together without treatments conflicting.
Co-occurrence of vitiligo and psoriasis is documented and more common than chance predicts. JAK inhibitors have evidence for both conditions, creating a treatment opportunity for patients with the overlap.
Perioral vitiligo — patches around the mouth — is highly visible, emotionally difficult, and presents specific treatment challenges distinct from lip vitiligo or general facial vitiligo. Here is what works and what to expect.
Clinical trials offer access to cutting-edge vitiligo treatments before they are widely approved, at no drug cost. Here is how to find active trials, assess eligibility, and understand what participation actually involves.
Vitiligo affects people of all skin tones, but the experience on darker skin is meaningfully different — higher contrast, greater stigma, and specific treatment considerations. Here is what the research and patient experience actually show.
Vitiligo developing or worsening during adolescence intersects with identity formation, peer perception, and school life in ways specific to this age group. Here is the treatment picture for teenagers and the broader context that matters.
Men with vitiligo face distinct challenges — beard patches, body hair concerns, cultural reluctance to seek help, and a different emotional landscape than women typically report. Here is what matters specifically for men with vitiligo.
